Antibiotic Pharmacokinetic and Pharmacodynamic Considerations in Patients With Kidney Disease

  • Rachel F. Eyler
    Department of Clinical, Social, and Administrative Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI
    Search for articles by this author
  • Bruce A. Mueller
    Address correspondence to Bruce A. Mueller, PharmD, FCCP, FASN, Department of Clinical, Social, and Administrative Sciences, College of Pharmacy, University of Michigan, 428 Church St., Ann Arbor, MI 48109-1065.
    Department of Clinical, Social, and Administrative Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI
    Search for articles by this author
      Although pharmacokinetic changes occurring in kidney disease are well described, pharmacodynamics in kidney disease is rarely considered. Knowledge of pharmacodynamic principles can allow a clinician to maximize an antibiotic's effectiveness while minimizing adverse effects and antibacterial resistance. An antibiotic's pharmacokinetic and pharmacodynamic profiles should drive dose adjustment decisions in patients with kidney disease. For example, although the half-lives of beta-lactams and aminoglycosides are both prolonged in these patients, beta-lactams exhibit time-dependent antibacterial activity; consequently, maintenance doses should be smaller but given at the same interval. In contrast, aminoglycosides are concentration-dependent antibiotics; hence prolongation of the dosing interval while using larger doses may be advantageous. The timing of drug administration in relation to hemodialysis may be used to achieve specific pharmacodynamic goals. Aminoglycosides given before hemodialysis generate high peaks, whereas subsequent dialytic drug removal minimizes the area under the serum concentration-time curve, potentially decreasing the risk of developing toxicity. Furthermore, new dialysis prescribing patterns (eg, automated peritoneal dialysis, nocturnal dialysis) affect pharmacokinetic and pharmacodynamic parameters in ways not appreciated by clinicians. Studies quantifying the often considerable drug removal with these therapies, as well as efforts to identify pharmacodynamic targets in patients with kidney disease are essential. This paper reviews pharmacodynamic as well as pharmacokinetic issues that should be considered when prescribing antibiotics to treat infections in this population.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Advances in Chronic Kidney Disease
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. United States Renal Data System: United States Renal Data System USRDS 2009 annual data report: Atlas of chronic kidney disease and end-stage renal disease in the United States. Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2009

        • Owens R.C.
        • Shorr A.F.
        Rational dosing of antimicrobial agents: Pharmacokinetic and pharmacodynamic strategies.
        Am J Health Syst Pharm. 2009; 66: S23-S30
        • Rybak M.J.
        • Abate B.J.
        • Kang S.L.
        • et al.
        Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity.
        Antimicrob Agents Chemother. 1999; 43: 1549-1555
        • Turnidge J.
        Pharmacodynamics and dosing of aminoglycosides.
        Infect Dis Clin North Am. 2003; 17: 503-528
        • Lacy M.K.
        • Nicolau D.P.
        • Nightingale C.H.
        • et al.
        The pharmacodynamics of aminoglycosides.
        Clin Infect Dis. 1998; 27: 23-27
        • Durante-Mangoni E.
        • Grammatikos A.
        • Utili R.
        • et al.
        Do we still need the aminoglycosides?.
        Int J Antimicrob Agents. 2009; 33: 201-205
        • Kirkpatrick C.M.
        • Duffull S.B.
        • Begg E.J.
        Pharmacokinetics of gentamicin in 957 patients with varying renal function dosed once daily.
        Br J Clin Pharmacol. 1999; 47: 637-643
        • Gilbert D.N.
        • Lee B.L.
        • Dworkin R.J.
        • et al.
        A randomized comparison of the safety and efficacy of once-daily gentamicin or thrice-daily gentamicin in combination with ticarcillin-clavulanate.
        Am J Med. 1998; 105: 182-191
        • Prins J.M.
        • Weverling G.J.
        • de Blok K.
        • et al.
        Validation and nephrotoxicity of a simplified once-daily aminoglycoside dosing schedule and guidelines for monitoring therapy.
        Antimicrob Agents Chemother. 1996; 40: 2494-2499
        • Nicolau D.P.
        • Freeman C.D.
        • Belliveau P.P.
        • et al.
        Experience with a once-daily aminoglycoside program administered to 2,184 adult patients.
        Antimicrob Agents Chemother. 1995; 39: 650-655
        • Anaizi N.
        Once-daily dosing of aminoglycosides. A consensus document.
        Int J Clin Pharmacol Ther. 1997; 35: 223-226
        • Xuan D.
        • Nicolau D.P.
        • Nightingale C.H.
        Population pharmacokinetics of gentamicin in hospitalized patients receiving once-daily dosing.
        Int J Antimicrob Agents. 2004; 23: 291-295
        • Vogelman B.
        • Gudmundsson S.
        • Leggett J.
        • et al.
        Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model.
        J Infect Dis. 1988; 158: 831-847
        • Aronoff G.R.
        • Bennett W.M.
        • Berns J.S.
        • et al.
        Drug Prescribing in Renal Failure.
        5th ed. American College of Physicians, Philadelphia, PA2007
        • Sowinski K.M.
        • Magner S.J.
        • Lucksiri A.
        • et al.
        Influence of hemodialysis on gentamicin pharmacokinetics, removal during hemodialysis, and recommended dosing.
        Clin J Am Soc Nephrol. 2008; 3: 355-361
        • Gailiunas Jr., P.
        • Dominguez-Moreno M.
        • Lazarus M.
        • et al.
        Vestibular toxicity of gentamicin. Incidence in patients receiving long-term hemodialysis therapy.
        Arch Intern Med. 1978; 138: 1621-1624
        • Feldman L.
        • Efrati S.
        • Eviatar E.
        • et al.
        Gentamicin-induced ototoxicity in hemodialysis patients is ameliorated by N-acetylcysteine.
        Kidney Int. 2007; 72: 359-363
        • Matsuo H.
        • Hayashi J.
        • Ono K.
        • et al.
        Administration of aminoglycosides to hemodialysis patients immediately before dialysis: A new dosing modality.
        Antimicrob Agents Chemother. 1997; 41: 2597-2601
        • Kamel Mohamed O.H.
        • Wahba I.M.
        • Watnick S.
        • et al.
        Administration of tobramycin in the beginning of the hemodialysis session: A novel intradialytic dosing regimen.
        Clin J Am Soc Nephrol. 2007; 2: 694-699
        • Dang L.
        • Duffull S.
        Development of a semimechanistic model to describe the pharmacokinetics of gentamicin in patients receiving hemodialysis.
        J Clin Pharmacol. 2006; 46: 662-673
        • Teigen M.M.
        • Duffull S.
        • Dang L.
        • et al.
        Dosing of gentamicin in patients with end-stage renal disease receiving hemodialysis.
        J Clin Pharmacol. 2006; 46: 1259-1267
        • O'Shea S.
        • Duffull S.
        • Johnson D.W.
        Aminoglycosides in hemodialysis patients: Is the current practice of post dialysis dosing appropriate?.
        Semin Dial. 2009; 22: 225-230
        • Gabardi S.
        • Abramson S.
        Drug dosing in chronic kidney disease.
        Med Clin North Am. 2005; 89: 649-687
        • Mueller B.A.
        • Brierton D.G.
        • Abel S.R.
        • et al.
        Effect of enteral feeding with ensure on oral bioavailabilities of ofloxacin and ciprofloxacin.
        Antimicrob Agents Chemother. 1994; 38: 2101-2105
        • Kays M.B.
        • Overholser B.R.
        • Mueller B.A.
        • et al.
        Effects of sevelamer hydrochloride and calcium acetate on the oral bioavailability of ciprofloxacin.
        Am J Kidney Dis. 2003; 42: 1253-1259
        • How P.P.
        • Fischer J.H.
        • Arruda J.A.
        • et al.
        Effects of lanthanum carbonate on the absorption and oral bioavailability of ciprofloxacin.
        Clin J Am Soc Nephrol. 2007; 2: 1235-1240
        • Ambrose P.G.
        • Bhavnani S.M.
        • Owens Jr., R.C.
        Clinical pharmacodynamics of quinolones.
        Infect Dis Clin North Am. 2003; 17: 529-543
        • Czock D.
        • Rasche F.M.
        Dose adjustment of ciprofloxacin in renal failure: Reduce the dose or prolong the administration interval?.
        Eur J Med Res. 2005; 10: 145-148
        • Blum R.A.
        Influence of renal function on the pharmacokinetics of lomefloxacin compared with other fluoroquinolones.
        Am J Med. 1992; 92: 18S-21S
        • Lodise T.P.
        • Lomaestro B.M.
        • Drusano G.L.
        Application of antimicrobial pharmacodynamic concepts into clinical practice: Focus on beta-lactam antibiotics: Insights from the society of infectious diseases pharmacists.
        Pharmacotherapy. 2006; 26: 1320-1332
        • Koomanachai P.
        • Bulik C.C.
        • Kuti J.L.
        • et al.
        Pharmacodynamic modeling of intravenous antibiotics against gram-negative bacteria collected in the United States.
        Clin Ther. 2010; 32: 766-779
        • Rybak M.J.
        • Lomaestro B.M.
        • Rotscahfer J.C.
        • et al.
        Vancomycin therapeutic guidelines: A summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists.
        Clin Infect Dis. 2009; 49: 325-327
        • CDC
        Staphylococcus aureus resistant to vancomycin––United States.
        MMWR. 2002; 51: 565
        • Steinkraus G.
        • White R.
        • Friedrich L.
        Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05.
        J Antimicrob Chemother. 2007; 60: 788-794
      2. Infectious Diseases Society of America: FDA lowers vancomycin breakpoints for Staphylococcus aureus. Available at: Accessed January 21, 2010

        • Mueller B.A.
        • Smoyer W.E.
        Challenges in developing evidence-based drug dosing guidelines for adults and children receiving renal replacement therapy.
        Clin Pharmacol Ther. 2009; 86: 479-482
      3. Vancomycin hydrochloride (vancomycin hydrochloride for injection) [package insert].
        Hospira, Lake Forest, IL2004
        • Scott M.K.
        • Mueller B.A.
        • Clark W.R.
        Vancomycin mass transfer characteristics of high-flux cellulosic dialysers.
        Nephrol Dial Transplant. 1997; 12: 2647-2653
        • MacGowan A.P.
        Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with gram-positive infections.
        J Antimicrob Chemother. 2003; 51: ii17-ii25
        • Vandecasteele S.J.
        • Boelaert J.R.
        • De Vriese A.S.
        Staphylococcus aureus infections in hemodialysis: What a nephrologist should know.
        Clin J Am Soc Nephrol. 2009; 4: 1388-1400
        • Safdar N.
        • Andes D.
        • Craig W.A.
        In vivo pharmacodynamic activity of daptomycin.
        Antimicrob Agents Chemother. 2004; 48: 63-68
      4. Bhavnani SM, Ambrose PG, Rubino CM, et al: Toxicodynamics of daptomycin in patients with bacteremia and/or endocarditis. Poster presented at: 46th International Conference on Antimicrobial Agents and Chemotherapy, San Francisco CA, September 27-30, 2006

      5. Cubicin [package insert].
        Cubist Pharmaceuticals Inc., Lexington, MAJanuary 2010
        • Vilay A.M.
        • Grio M.
        • DePestel D.D.
        • et al.
        Daptomycin pharmacokinetics in patients treated with continuous venovenous hemodialysis [abstract].
        J Am Soc Nephrol. 2008; 19: 691A
        • Salama N.N.
        • Segal J.H.
        • Churchwell M.D.
        • et al.
        Single-dose daptomycin pharmacokinetics in chronic haemodialysis patients.
        Nephrol Dial Transplant. 2010; 25: 1279-1284
        • Salama N.N.
        • Segal J.H.
        • Churchwell M.D.
        • et al.
        Intradialytic administration of daptomycin in end stage renal disease patients on hemodialysis.
        Clin J Am Soc Nephrol. 2009; 4: 1190-1194
        • Chakraborty A.
        • Roy S.
        • Loeffler J.
        • et al.
        Comparison of the pharmacokinetics, safety and tolerability of daptomycin in healthy adult volunteers following intravenous administration by 30 min infusion or 2 min injection.
        J Antimicrob Chemother. 2009; 64: 151-158
        • Hegde S.S.
        • Reyes N.
        • Wiens T.
        • et al.
        Pharmacodynamics of Telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria.
        Antimicrob Agents Chemother. 2004; 48: 3043-3050
        • Andes D.
        • Craig W.A.
        In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
        Antimicrob Agents Chemother. 2007; 51: 1633-1642
      6. Vibativ [package insert].
        Astellas Pharma Inc, Deerfield, ILSeptember 2009
        • Attwood R.J.
        • LaPlante K.L.
        Telavancin: A novel lipoglycopeptide antimicrobial agent.
        Am J Health Syst Pharm. 2007; 64: 2335-2348
        • Patel J.H.
        • Churchwell M.D.
        • Seroogy J.D.
        • et al.
        Telavancin and hydroxyl propyl-beta-cyclodextrin clearance during continuous renal replacement therapy: An in vitro study.
        Int J Artif Organs. 2009; 32: 745-751
        • Stryjewski M.E.
        • Graham D.R.
        • Wilson S.E.
        • et al.
        Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms.
        Clin Infect Dis. 2008; 46: 1683-1693
        • Marbury T.
        • Dowell J.A.
        • Seltzer E.
        • et al.
        Pharmacokinetics of dalbavancin in patients with renal or hepatic impairment.
        J Clin Pharmacol. 2009; 49: 465-476
      7. Vilay AM, Shah KH, Churchwell MD, et al: Modeled dalbavancin transmembrane clearance during intermittent and continuous renal replacement therapies. Blood Purif (in press)

        • Lok C.E.
        Avoiding trouble down the line: The management and prevention of hemodialysis catheter-related infections.
        Adv Chronic Kidney Dis. 2006; 13: 225-244
        • National Kidney Foundation (KDOQI)
        Clinical practice guidelines and clinical practice recommendations for 2006 updates: Hemodialysis adequacy, peritoneal dialysis adequacy and vascular access.
        Am J Kidney Dis. 2006; 48: S1-S322
        • Bearthard G.A.
        • Urbanes A.
        Infection associated with tunneled hemodialysis catheters.
        Semin Dial. 2008; 21: 528-538
        • Troidle L.
        • Finkelstein F.O.
        Catheter-related bacteremia in hemodialysis patients: The role of the central venous catheter in prevention and therapy.
        Int J Artif Organs. 2008; 31: 827-833
        • Sowinski K.M.
        • Mueller B.A.
        • Grabe D.W.
        • et al.
        Cefazolin dialytic clearance by high-efficiency and high-flux hemodialyzers.
        Am J Kidney Dis. 2001; 37: 766-776
        • Stryjewski M.E.
        • Szczech L.A.
        • Benjamin D.K.
        • et al.
        Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia.
        Clin Infect Dis. 2007; 44: 190-196
        • Scott M.K.
        • Mueller B.A.
        • Sowinski K.M.
        • et al.
        Dialyzer-dependent changes in solute and water permeability with bleach reprocessing.
        Am J Kidney Dis. 1999; 33: 87-96
        • Scott M.K.
        • Mueller B.A.
        • Sowinski K.M.
        The effects of peracetic acid-hydrogen peroxide reprocessing on dialyzer solute and water permeability.
        Pharmacotherapy. 1999; 19: 1042-1049
        • Decker B.S.
        • Mueller B.A.
        • Sowinski K.M.
        Drug dosing considerations in alternative hemodialysis.
        Adv Chronic Kidney Dis. 2007; 14: e17-e26
        • Yeung S.M.
        • Walker S.E.
        • Tailor S.A.
        • et al.
        Pharmacokinetics of oral ciprofloxacin in continuous cycling peritoneal dialysis.
        Perit Dial Int. 2004; 24: 447-453
        • Dahl N.V.
        • Foote E.F.
        • Searson K.M.
        • et al.
        Pharmacokinetics of intraperitoneal fluconazole during continuous cycling peritoneal dialysis.
        Ann Pharmacother. 1998; 32: 1284-1289
        • Brophy D.F.
        • Sowinski K.M.
        • Kraus M.A.
        • et al.
        Small and middle molecular weight solute clearance in nocturnal intermittent peritoneal dialysis.
        Perit Dial Int. 1999; 19: 534-539